Cogent Biosciences Net Worth
Cogent Biosciences Net Worth Breakdown | COGT |
Cogent Biosciences Net Worth Analysis
Cogent Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Cogent Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Cogent Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Cogent Biosciences' net worth analysis. One common approach is to calculate Cogent Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Cogent Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Cogent Biosciences' net worth. This approach calculates the present value of Cogent Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Cogent Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Cogent Biosciences' net worth. This involves comparing Cogent Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Cogent Biosciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Cogent Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cogent Biosciences' net worth research are outlined below:
| Cogent Biosciences generated a negative expected return over the last 90 days | |
| Cogent Biosciences has high historical volatility and very poor performance | |
| Net Loss for the year was (192.41 M) with loss before overhead, payroll, taxes, and interest of (121.63 M). | |
| Cogent Biosciences currently holds about 325.56 M in cash with (153.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95. | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Ferrante Karen Jean of 2513 shares of Cogent Biosciences at 8.02 subject to Rule 16b-3 |
Cogent Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cogent Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cogent Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Cogent Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cogent Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cogent Biosciences backward and forwards among themselves. Cogent Biosciences' institutional investor refers to the entity that pools money to purchase Cogent Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Adage Capital Partners Gp Llc | 2024-06-30 | 4.2 M | State Street Corp | 2024-06-30 | 3.8 M | Deerfield Management Co | 2024-09-30 | 3.7 M | Sofinnova Ventures | 2024-06-30 | 2.8 M | Geode Capital Management, Llc | 2024-09-30 | 2.3 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2 M | Saturn V Capital Management Llc | 2024-09-30 | 1.7 M | Octagon Capital Advisors Lp | 2024-09-30 | 1.3 M | Millennium Management Llc | 2024-06-30 | 1.2 M | Point72 Asset Management, L.p. | 2024-09-30 | 10.5 M | Kynam Capital Management, Lp | 2024-09-30 | 9.2 M |
Follow Cogent Biosciences' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.06 B.Market Cap |
|
Project Cogent Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.61) | (0.64) | |
| Return On Capital Employed | (0.76) | (0.79) | |
| Return On Assets | (0.61) | (0.64) | |
| Return On Equity | (0.75) | (0.78) |
When accessing Cogent Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Cogent Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cogent Biosciences' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Cogent Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cogent Biosciences. Check Cogent Biosciences' Beneish M Score to see the likelihood of Cogent Biosciences' management manipulating its earnings.
Evaluate Cogent Biosciences' management efficiency
Cogent Biosciences has return on total asset (ROA) of (0.4402) % which means that it has lost $0.4402 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7847) %, meaning that it created substantial loss on money invested by shareholders. Cogent Biosciences' management efficiency ratios could be used to measure how well Cogent Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.64 in 2024. Return On Capital Employed is likely to drop to -0.79 in 2024. At this time, Cogent Biosciences' Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 14.4 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 21.1 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.24 | 3.07 | |
| Tangible Book Value Per Share | 3.24 | 3.07 | |
| Enterprise Value Over EBITDA | (2.11) | (2.00) | |
| Price Book Value Ratio | 1.82 | 1.23 | |
| Enterprise Value Multiple | (2.11) | (2.00) | |
| Price Fair Value | 1.82 | 1.23 | |
| Enterprise Value | 502.9 M | 528.1 M |
At Cogent Biosciences, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 925.407 | Quarterly Revenue Growth (1.00) | Return On Equity (0.78) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cogent Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cogent Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cogent Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cogent Biosciences Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 2nd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 13th of June 2024 An amendment to the original Schedule 13D filing | ViewVerify |
Cogent Biosciences Earnings per Share Projection vs Actual
Cogent Biosciences Corporate Management
| Rachael MD | VP Development | Profile | |
| Sara Saltzman | VP Affairs | Profile | |
| Jessica MD | Chief Officer | Profile | |
| Brad Fell | Senior Chemistry | Profile | |
| Christi Waarich | Senior Relations | Profile | |
| Brad Barnett | Chief Officer | Profile |
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.